Cullinan Oncology Q1 net loss $12.9M; Taiho deal adds $275M, extends cash runway through 2026

Cullinan Therapeutics, Inc.

2023-Q1 EPS reported -$0.27

Cash and investments $410M at March 31, 2022; $685M including $275M Taiho upfront; runway extended to 2026.
Net loss $12.9M vs $34.2M Q4 2021; R&D expense $24.5M, G&A $8.1M.
CLN-081 co-development deal with Taiho: $275M upfront, up to $130M milestones, 50/50 US profit share.
CLN-081 granted Breakthrough Therapy Designation; 41% confirmed ORR at 100mg BID; ASCO oral June 2022.
IND filings for CLN-617 and CLN-978 on track for H1 2023; CLN-049 and CLN-619 Phase 1 dosing ongoing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.